Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-08-12), Aceso Life Science Group's Beta is 0.5720.
Aceso Life Science Group (HKSE:00474) Beta Explanation
Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.
Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Rental & Leasing Services subindustry, Aceso Life Science Group's Beta, along with its competitors' market caps and Beta data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aceso Life Science Group Beta vs Business Services Industry
For the Business Services industry and Industrials sector, Aceso Life Science Group's Beta distribution charts can be found below:
* The bar in red indicates where Aceso Life Science Group's Beta falls into.
Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.
Aceso Life Science Group (HKSE:00474) has a Beta of 0.5720 as of Aug. 12, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Aceso Life Science Group and its competitors.
Is Aceso Life Science Group's Beta too high?
Aceso Life Science Group's current Beta is 0.5720. Overall, Aceso Life Science Group has a GF Score™ of 19/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aceso Life Science Group's Beta compare to URI and SUNB?
Aceso Life Science Group's Beta of 0.5720 can be compared against companies in the Business Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Business Services company?
A good Beta depends on the Business Services industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Aceso Life Science Group and its competitors. Aceso Life Science Group's current Beta is 0.5720. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aceso Life Science Group stock overvalued right now?
Based on GuruFocus' analysis, Aceso Life Science Group (HKSE:00474) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.08, compared to a current price of HK$0.11 — trading 42.5% above its estimated fair value. The current Beta is 0.5720. Aceso Life Science Group's overall GF Score™ is 19/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Aceso Life Science Group (HKSE:00474), the current Beta is 0.5720 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aceso Life Science Group (HKSE:00474) Overvalued in 2026?
Based on GuruFocus' analysis, Aceso Life Science Group stock appears to be overvalued.
The current stock price of HK$0.11 is trading 42.5% above its estimated GF Value™ of HK$0.08.
GuruFocus considers Aceso Life Science Group to be Significantly Overvalued.
Key valuation signals for HKSE:00474:
Beta: 0.5720
GF Value™: HK$0.08 vs. price of HK$0.11 (42.5% above fair value)
No single metric tells the full story. See the HKSE:00474 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aceso Life Science Group Ltd is an investment holding company. The group's operating segments include Money lending, Rental and sale of construction machinery and spare parts business, Provision of repair and maintenance and transportation service business, Provision of asset management, securities brokerage, commodities, futures, and other financial service business, Property leasing business, and Property development business. It derives key revenue from the rental and sale of construction machinery and spare parts. Geographically, the group has a business presence in Hong Kong, the UK, the PRC, Macau, and Cambodia.
19GF Score
Get the complete analysis for HKSE:00474
Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:00474 has been successfully added to your 
